Novo shutters 2 more heart disease studies, indicating IL-6 is ‘invalid target’
Novo Nordisk (NVO) halted two late-stage heart disease studies, HERMES and ATHENA, citing expected futility. This follows the failure of its ZEUS trial in July. Analysts now consider IL-6 an invalid target for cardiovascular disease. Novo's stock dipped 2% to $45.59. The ARTEMIS trial continues, with results expected in early 2024.
How this was made
The 30-second read
Why it matters
The terminations signal a strategic setback for Novo's heart‑failure program and may lead to a short‑term stock decline, but the company's broader portfolio could cushion the impact.
Market read
The news directly affects Novo Nordisk (NVO) and indirectly influences other biotech firms targeting IL‑6, as well as broader cardiovascular‑focused investment themes.
What to watch
Novo Nordisk's core obesity and diabetes businesses remain strong, and the company still has a pipeline of other growth drivers.
Background
Novo Nordisk, a leading Danish pharma, has been developing an IL‑6 inhibitor (ziltivekimab) for cardiovascular disease. Earlier this year the ZEUS trial failed, and now two additional Phase 3 studies are being stopped.
Ticker impact
Novo Nordisk announced the early termination of two Phase 3 heart failure trials (HERMES and ATHENA) for its IL-6 inhibitor, indicating a material setback for its cardiovascular program.
downward pressure, potential 2‑4% decline over the next few days
Multiple late‑stage trials were halted on futility, and analysts already expect the shares to be mildly pressured.
Market effects
The setbacks raise doubts about IL‑6 as a viable target for cardiovascular disease, potentially affecting other biotech firms pursuing similar pathways.
European and U.S. biotech indices may see modest downside pressure.
Limited to the cardiovascular‑inflammation niche; broader market impact is minimal.
Counterpoint
If the upcoming ARTEMIS trial shows a signal, the market could quickly rebound, making the current dip a buying opportunity.
Key entities
- CompanyNovo Nordisk
Danish pharmaceutical company developing IL‑6 inhibitor ziltivekimab.
- Analyst FirmOppenheimer
Provided commentary on the trial terminations.
